Active substance
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| RENAGEL 800MG F.C.TABLET | 800 mg | Film-coated tablet · Oral use | 180 Bottle | SAR 980.40 | NCE · Prescription | GENZYME | Withdrawn by MAH · Not Marketed |
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| RENAGEL | 400MG; 800MG | tablet · oral | GENZYME | Prescription | 12 Jul 2000 |
| SEVELAMER HYDROCHLORIDE | 400MG; 800MG | tablet · oral | GLENMARK PHARMS LTD | Prescription | 8 Feb 2019 |
| SEVELAMER HYDROCHLORIDE | 400MG; 800MG | tablet · oral | LUPIN | Prescription | 16 Jun 2021 |
| SEVELAMER HYDROCHLORIDE | 400MG; 800MG | tablet · oral | MACLEODS PHARMS | Prescription | 26 May 2023 |
| SEVELAMER HYDROCHLORIDE | 400MG; 800MG | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 11 Jul 2023 |
| SEVELAMER HYDROCHLORIDE | 800MG | tablet · oral | NAVINTA LLC | Prescription | 3 Feb 2025 |
| RENAGEL | 403MG | capsule · oral | GENZYME | Discontinued | 30 Oct 1998 |
| SEVELAMER HYDROCHLORIDE | 400MG; 800MG | tablet · oral | RISING | Discontinued | 15 Dec 2020 |
Renagel is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
Tasermity is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Sevelamer hydrochloride should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| RENAGEL | 02244310 | 800 MG | TABLET · ORAL | SANOFI-AVENTIS CANADA INC |
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | SEVELAMER 0.8 GM POWDER PACKET | $0.91959 | per EA | 23 Sep 2026 |
| US NADAC | SEVELAMER 2.4 GM POWDER PACKET | $1.00501 | per EA | 23 Sep 2026 |
| US NADAC | SEVELAMER HCL 800 MG TABLET | $0.69517 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Sevelamer 2.4g oral powder sachets sugar free | £167.04 | 60 sachet | 1 Oct 2026 |
| NHS Drug Tariff | Sevelamer 800mg oral powder sachets sugar free | £83.52 | 90 sachet | 1 Oct 2026 |
| NHS Drug Tariff | Sevelamer 800mg tablets | £28.58 | 180 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.